Eyeworld Daily News

© 2020 Allergan. All rights reserved. All trademarks are the property of their respective owners. DUR133196 03/20 INTRODUCING THE LATEST INNOVATION IN GLAUCOMA MANAGEMENT 1 : The first and only FDA-approved, biodegradable, intracameral implant indicated to reduce IOP in patients with open angle glaucoma or ocular hypertension via a sustained-release drug delivery system. 1,2 I Visit DurystaHCP.com to learn more. NOW APPROVE INDICATIONS AND USAGE DURYSTA ™ (bimatoprost implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). IMPORTANT SAFETY INFORMATION Contraindications DURYSTA ™ is contraindicated in patients with: active or suspected ocular or periocular infections; corneal endothelial cell dystrophy (e.g., Fuchs' Dystrophy); prior corneal transplantation or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]); absent or ruptured posterior lens capsule, due to the risk of implant migration into the posterior segment; hypersensitivity to bimatoprost or to any other components of the product. Warnings and Precautions The presence of DURYSTA ™ implants has been associated with corneal adverse reactions and increased risk of corneal endothelial cell loss. Administration of DURYSTA ™ should be limited to a single implant per eye without retreatment. Caution should be used when prescribing DURYSTA ™ in patients with limited corneal endothelial cell reserve. DURYSTA ™ should be used with caution in patients with narrow iridocorneal angles (Shaffer grade < 3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle. Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic bimatoprost, including DURYSTA ™ intracameral implant. DURYSTA ™ should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. Prostaglandin analogs, including DURYSTA ™ , have been reported to cause intraocular inflammation. DURYSTA ™ should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated. Ophthalmic bimatoprost, including DURYSTA ™ intracameral implant, has been reported to cause changes to pigmented tissues, such as increased pigmentation of the iris. Pigmentation of the iris is likely to be permanent. Patients who receive treatment should be informed of the possibility of increased pigmentation. While treatment with DURYSTA ™ can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly. Intraocular surgical procedures and injections have been associated with endophthalmitis. Proper aseptic technique must always be used with administering DURYSTA ™ , and patients should be monitored following the administration. Adverse Reactions In controlled studies, the most common ocular adverse reaction reported by 27% of patients was conjunctival hyperemia. Other common adverse reactions reported in 5%-10% of patients were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure increased, corneal endothelial cell loss, vision blurred, iritis, and headache. Please see Brief Summary of full Prescribing Information on the following page. References: 1. Allergan receives FDA approval for DURYSTA™ (bimatoprost implant) the first and only intracameral biodegradable sustained-release implant to lower intraocular pressure in open-angle glaucoma or ocular hypertension patients [press release]. Dublin: PR Newswire; March 5, 2020. 2. DURYSTA™ [Prescribing Information]. Irvine, CA: Allergan, Inc.; 2020. IOP=intraocular pressure.

• Cover